{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:52:13Z","timestamp":1779889933321,"version":"3.53.1"},"reference-count":17,"publisher":"S. Karger AG","issue":"1-2","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> The study sought to assess the effect of treatment with mineralocorticoid receptor antagonists (MRAs) on long-term prognosis of patients with systolic heart failure (HF) surviving index episodes of ventricular tachyarrhythmias. <b><i>Methods:<\/i><\/b> A large retrospective registry was used including consecutive HF patients with left ventricular ejection fraction &#x3c;45% and index episodes of ventricular tachyarrhythmias from 2002 to 2015. The primary endpoint was all-cause mortality at 3 years and secondary endpoints were rehospitalization, as well as the composite endpoint consisting of recurrent ventricular tachyarrhythmias, sudden cardiac death and appropriate implantabe cardioverter defibrillator (ICD) therapies at 3 years. <b><i>Results:<\/i><\/b> 748 patients were included, 20% treated with MRA and 80% without. At 3 years, treatment with MRA was not associated with improved all-cause mortality (22% vs. 24%, log-rank <i>p<\/i> = 0.968; hazard ratio (HR) = 1.008; 95% CI 0.690\u20131.472; <i>p<\/i> = 0.968). Accordingly, risk of the composite endpoint (28% vs. 27%; HR = 1.131; 95% CI 0.806\u20131.589; <i>p<\/i> = 0.476) and first cardiac rehospitalization (24% vs. 22%; HR = 1.139; 95% CI 0.788\u20131.648; <i>p<\/i> = 0.489) were not affected by treatment with MRA. <b><i>Conclusion:<\/i><\/b> In patients with ventricular tachyarrhythmias, treatment with MRA was not associated with improved all-cause mortality at 3 years. The therapeutic effect of MRA treatment in patients with ventricular tachyarrhythmias needs to be reinvestigated within further randomized controlled trials. <\/jats:p>","DOI":"10.1159\/000520310","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T22:01:17Z","timestamp":1639000877000},"page":"35-45","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias"],"prefix":"10.1159","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7617","authenticated-orcid":false,"given":"Tobias","family":"Schupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"von Zworowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abumayyaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambis","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed L.","family":"Abba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5970-0093","authenticated-orcid":false,"given":"Michael","family":"Behnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1378-0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-018-6812-z"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euw295"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12635"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.900"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft134"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021799"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv366"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081753"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.112.970566"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.09.009"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107920"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0198-2"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006540"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/520310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/520310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:28:07Z","timestamp":1745422087000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000520310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":17,"journal-issue":{"issue":"1-2","published-online":{"date-parts":[[2022,1,6]]},"published-print":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.1159\/000520310","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"value":"0031-7012","type":"print"},{"value":"1423-0313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]}}}